Screener
Mirum Pharmaceuticals, Inc. MIRM Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Mirum Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001759425-26-000045
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Operating activities | ||
| Net loss | $(857,382) | $(20,538) |
| Reconciliation of net loss to net cash (used in) provided by operating activities: | ||
| Stock-based compensation | 66,775 | 34,271 |
| Depreciation and amortization | 13,810 | 12,108 |
| Amortization of debt discount and offering costs | 1,112 | 860 |
| Unrealized foreign exchange loss (gain) | 1,994 | (1,270) |
| Non-cash lease expense | 1,145 | 826 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Mirum Pharmaceuticals, Inc.'s stock-based comp?
- Mirum Pharmaceuticals, Inc. (MIRM) reported stock-based comp of $30.57M in Q2 2026.
- How has Mirum Pharmaceuticals, Inc.'s stock-based comp changed year-over-year?
- Mirum Pharmaceuticals, Inc.'s stock-based comp increased by 65.5% year-over-year, from $18.47M to $30.57M.
- What is the long-term trend for Mirum Pharmaceuticals, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Mirum Pharmaceuticals, Inc.'s stock-based comp has grown at a 32.6% compound annual growth rate (CAGR), from $23.09M to $71.42M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Mirum Pharmaceuticals, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude